Hoth Therapeutics (HOTH) Receives New Coverage from Analysts at Laidlaw

Research analysts at Laidlaw assumed coverage on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report issued on Monday, reports. The firm set a “buy” rating and a $10.00 price target on the stock. Laidlaw’s price target indicates a potential upside of 88.68% from the company’s previous close.

Shares of HOTH opened at $5.30 on Monday. Hoth Therapeutics has a twelve month low of $4.51 and a twelve month high of $13.88.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures.

Featured Story: Why Invest in Dividend Achievers?

Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with's FREE daily email newsletter.